AIO-Studien-gGmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
- Conditions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 1086
- Registration Number
- NCT04172467
- Locations
- 🇩🇪
Privatärztliche Praxis; Innere Medizin, Hämatologie, Internistische Onkologie, Kaiserslautern, Germany
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology
- Conditions
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 56
- Registration Number
- NCT04046614
- Locations
- 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany
A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 54
- Registration Number
- NCT03620123
- Locations
- 🇩🇪
Essen University Hospital, Essen, Germany
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 49
- Registration Number
- NCT03572582
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 128
- Registration Number
- NCT03473574
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 270
- Registration Number
- NCT03468335
- Locations
- 🇩🇪
Städtisches Klinikum Brandenburg, Brandenburg, Germany
🇩🇪MVZ Onkologische Kooperation Harz, Goslar, Germany
🇩🇪Ambulantes Therapiezentrum Hämatologie / Onkologie, Offenburg, Germany
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 66
- Registration Number
- NCT03416244
- Locations
- 🇩🇪
Universitätsmedizin Mannheim, Heidelberg University, II. Medizinische Klinik, Mannheim, Germany
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 97
- Registration Number
- NCT03409848
- Locations
- 🇩🇪
Klinikum Wolfsburg - Med. II, Wolfsburg, Germany
🇩🇪Stauferklinikum Schwäbisch Gmünd - Innere Med., Mutlangen, Germany
🇩🇪Klinikum rechts der Isar der TU München - Innere Med. III, München, Germany
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 200
- Registration Number
- NCT03345810
- Locations
- 🇩🇪
Klinikum Darmstadt, Darmstadt, Germany
🇩🇪DRK-Kliniken Berlin Mitte, Berlin-Mitte, Germany
🇩🇪Gesundheitszentrum St. Marien GmbH, Amberg, Germany
A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 67
- Registration Number
- NCT03331640
- Locations
- 🇩🇪
Praxis für Innere Medizin, Friedrichshafen, Germany